Tags: Drug.

Denufosol (INN) is an inhaled drug for the treatment of cystic fibrosis being developed by Inspire Pharmaceuticals and sponsored by the Cystic Fibrosis Foundation. It was tested in two Phase III clinical trials TIGER-1 and TIGER-2. Initially in the first Phase III trial TIGER-1 the compound showed significant results as compared with placebo.

Denufosol.svg
ATC prefix
none
CAS number
211448-85-0
FDA UNII code
5PC250KSSH
IUPAC name
(3S5R)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R3S4R5R)-5-(24-dioxopyrimidin-1-yl)-34-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate
PubChem
192708

Loading...

This page contains content from the copyrighted Wikipedia article "Denufosol"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.